6 recruiting, 3 completed, 2 not yet recruiting, 1 terminated. 14 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Recruiting 6, Completed 3, Not yet recruiting 2, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 3 | Recruiting 2, Terminated 1 |
Follow Locally Advanced Non-Small Cell Lung Cancer: new trials by email Literature Review of Locally Advanced Non-Small Cell Lung Cancer trials Research Report on Locally Advanced Non-Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of DS-3939a in Participants With Solid Tumors DS-3939a, Pembrolizumab, Carboplatin - Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 400 | 2026-10-13 | 2026-10-28 |
| Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz - Non Small Cell Lung Cancer, Cardiotoxicity | Phase 2 | Recruiting | Indiana University | 10 | 2026-09-01 | 2026-09-15 |
| Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC Sintilimab, Paclitaxel, Carboplatin (AUC 5) - Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer | Phase 2 | Recruiting | Yang Hong | 28 | 2025-12-31 | 2026-04-30 |
| Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC Fumetinib combined platinum-based double chemotherapy, Concurrent Radiochemotherapy - EGFR, NSCLC (Non-small Cell Lung Cancer) | Phase 2 | Recruiting | Peng Zhang | 160 | 2025-11-25 | 2026-08-03 |
| Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC PM8002, Sintilimab, Nab-paclitaxel - Locally Advanced Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 160 | 2025-02-18 | 2025-02-20 |
| Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer Befotertinib combined Bevacizumab, Befotertinib combined platinum-based double chemotherapy - EGFR, Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Peng Zhang | 60 | 2024-11-07 | 2025-01-06 |
| Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT Anlotinib - Locally Advanced Non-Small Cell Lung Cancer, Thoracic Radiotherapy | Phase 2 | Completed | JIANYANG WANG | 44 | 2024-01-01 | 2026-10-07 |
| Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer Induction chemoimmunotherapy, Concurrent chemoradiotherapy (cCRT), consolidation immunotherapy - Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Shanghai Chest Hospital | 108 | 2022-10-09 | 2026-07-23 |
| Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer Anlotinib, Chemotherapy, Radiotherapy - Locally Advanced Non-small Cell Lung Cancer, Efficacy and Safety | Phase 2 | Withdrawn | Sun Yat-sen University | 2022-04-01 | 2022-11-21 | |
| A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy Camrelizumab, PD-1 monoclonal antibody, Apatinib, VEGFR2 antibody - Locally Advanced Non-Small Cell Lung Cancer | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 42 | 2021-03-17 | 2022-08-16 |
| Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC Pembrolizumab, Cis Platinum, Carboplatin - Locally Advanced Non-small Cell Lung Cancer | Phase 2 | Not yet recruiting | Kobe Minimally Invasive Cancer Center | 21 | 2019-12-01 | 2019-11-06 |
| Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy Paclitaxel, Carboplatin and Bevacizumab,Erlotinib - Locally Advanced Non-Small Cell Lung Cancer, NSCLC | Phase 2 | Completed | Radboud University Medical Center | 35 | 2008-09-01 | 2013-07-15 |
| A Phase II Trial of Cisplatin-Docetaxel Induction Plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy Docetaxel, concomitant radiotherapy, Cisplatin - Locally Advanced Non-small Cell Lung Cancer | Phase 2 | Completed | Centre Antoine Lacassagne | 44 | 2004-08-05 | 2017-12-13 |
| Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer Proton Radiation Therapy, Taxol, Carboplatin - Locally Advanced Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Loma Linda University | 28 | 1999-08-01 | 2014-05-22 |
Carcinoma, Non-Small-Cell Lung (10) · Cardiotoxicity (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Radiation Injuries (1)
Bronchial Neoplasms (10) · Carcinoma, Bronchogenic (10) · Lung Diseases (10) · Lung Neoplasms (10) · Neoplasms (10) · Neoplasms by Site (10) · Respiratory Tract Diseases (10) · Respiratory Tract Neoplasms (10) · Thoracic Neoplasms (10) · Cardiovascular Diseases (1) · Chemically-Induced Disorders (1) · Drug-Related Side Effects and Adverse Reactions (1) · Heart Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Carboplatin (6) · Chemoradiotherapy (3) · Paclitaxel (3) · Pemetrexed (3) · Cisplatin (2) · anlotinib (2) · pembrolizumab (2) · sintilimab (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Docetaxel (1) · Drug Therapy (1) · Erlotinib Hydrochloride (1) · Immunotherapy (1)
Peng Zhang (2) · Centre Antoine Lacassagne (1) · Chinese Academy of Medical Sciences (1) · Daiichi Sankyo (1) · Indiana University (1) · JIANYANG WANG (1) · Kobe Minimally Invasive Cancer Center (1) · Loma Linda University (1) · Radboud University Medical Center (1) · Shanghai Chest Hospital (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · Sun Yat-sen University (1) · Yang Hong (1)
China (9) · United States (3) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · France (1) · Italy (1) · Japan (1) · Netherlands (1) · Spain (1) · Taiwan (1) · Tunisia (1) · Turkey (Türkiye) (1)
Akito Hata (1) · David A. Bush, MD (1) · Hui Liu, Professor (1) · J. Timmer-Bonte, MD, Phd (1) · Jerry D. Slater, MD (1) · Jordan Holmes, MD (1) · Peng Zhang, PhD (1)
PMID 11698646, PMID 15030777, PMID 15240681, PMID 15358536, PMID 15771580, PMID 15800326, PMID 16227604, PMID 18565862, PMID 19426218, PMID 19515503, PMID 20516428, PMID 20530281, PMID 20625120, PMID 20636820, PMID 22867890, PMID 23775348, PMID 24422706, PMID 25601342, PMID 27718847, PMID 27745820, PMID 28271869, PMID 28397821, PMID 28885881, PMID 29454091, PMID 29556198, PMID 29570421, PMID 29658848, PMID 29658856, PMID 30206369, PMID 30207593, PMID 30280635, PMID 30285770, PMID 31331945, PMID 32366856, PMID 32577817, PMID 33294918, PMID 33438349, PMID 33476803, PMID 34377028, PMID 41082893